{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:23:52Z","timestamp":1789604632631,"version":"build-2803163510"},"reference-count":24,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2015,6,8]],"date-time":"2015-06-08T00:00:00Z","timestamp":1433721600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005616","name":"Allergan, Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100005616","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100013988","name":"Dermira","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100013988","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Miramar Labs, Inc."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatric Dermatology"],"published-print":{"date-parts":[[2015,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>To evaluate the efficacy and safety of onabotulinumtoxinA in adolescents with primary axillary hyperhidrosis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This 52\u2010week, multicenter, nonrandomized, open\u2010label study was conducted in 141 adolescents ages 12 to 17 years with severe primary axillary hyperhidrosis. Patients could receive up to six treatments with onabotulinumtoxinA (50\u00a0U per axilla), with re\u2010treatment occurring no sooner than 8\u00a0weeks after the prior treatment cycle and no later than 44\u00a0weeks after the initial treatment cycle. The primary efficacy measure was treatment response, based on self\u2010assessed hyperhidrosis severity following the first two treatments using the 4\u2010point Hyperhidrosis Disease Severity Scale (<jats:styled-content style=\"fixed-case\">HDSS<\/jats:styled-content>). Other efficacy measures included spontaneous resting sweat production and health outcomes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Fifty\u2010six (38.9%) participants underwent one treatment, 59 (41.0%) underwent two, 20 (13.9%) underwent three, 6 (4.2%) underwent four, and 3 (2.1%) underwent five. OnabotulinumtoxinA significantly improved <jats:styled-content style=\"fixed-case\">HDSS<\/jats:styled-content> scores and decreased sweat production compared with treatment cycle baselines. Seventy\u2010nine patients (54.9%) responded to treatment based on <jats:styled-content style=\"fixed-case\">HDSS<\/jats:styled-content> criteria. From 56.6% to 72.3% of patients experienced a two\u2010grade or more improvement at 4 and 8\u00a0weeks after each of the first two treatments. The majority (79.4%\u201393.2%) had a 75% or greater reduction in sweat production at week 4 (treatments 1\u20133). The median duration of effect for responders ranged from 134 to 152\u00a0days. Using quality of life measures, health outcomes improved markedly. Eight patients (5.6%) had mild or moderate treatment\u2010related adverse events. No unexpected safety signals were observed in this study. Neutralizing antibodies to onabotulinumtoxinA did not develop.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>OnabotulinumtoxinA injections provided beneficial effects in adolescents with primary axillary hyperhidrosis.<\/jats:p><\/jats:sec>","DOI":"10.1111\/pde.12620","type":"journal-article","created":{"date-parts":[[2015,6,11]],"date-time":"2015-06-11T03:23:55Z","timestamp":1433993035000},"page":"609-617","source":"Crossref","is-referenced-by-count":24,"title":["A Prospective, Nonrandomized, Open\u2010Label Study of the Efficacy and Safety of OnabotulinumtoxinA in Adolescents with Primary Axillary Hyperhidrosis"],"prefix":"10.1111","volume":"32","author":[{"given":"Dee Anna","family":"Glaser","sequence":"first","affiliation":[{"name":"Department of Dermatology Saint Louis University St. Louis Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Pariser","sequence":"additional","affiliation":[{"name":"Department of Dermatology Eastern Virginia Medical School Norfolk Virginia"},{"name":"Virginia Clinical Research, Inc. Norfolk Virginia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adelaide A.","family":"Hebert","sequence":"additional","affiliation":[{"name":"Department of Dermatology University of Texas\u2013Houston Medical School Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Landells","sequence":"additional","affiliation":[{"name":"Memorial University of Newfoundland St. John's Newfoundland Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Somogyi","sequence":"additional","affiliation":[{"name":"Allergan, Inc. Irvine California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Weng","sequence":"additional","affiliation":[{"name":"Allergan, Inc. Irvine California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell F.","family":"Brin","sequence":"additional","affiliation":[{"name":"Allergan, Inc. Irvine California"},{"name":"Department of Neurology University of California at Irvine Irvine California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick","family":"Beddingfield","sequence":"additional","affiliation":[{"name":"Allergan, Inc. Irvine California"},{"name":"Division of Dermatology Department of Medicine David Geffen School of Medicine University of California at Los Angeles Los Angeles California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,6,8]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2003.12.040"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.sder.2010.03.004"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1470.2008.00782.x"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.1040708"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.det.2014.06.005"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.det.2014.06.004"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4725.2006.32334.x"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00105-011-2225-7"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200102153440704"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.323.7313.596"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.det.2014.06.003"},{"key":"e_1_2_6_13_1","volume-title":"Botox [package insert]","year":"2013"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.1996.tb00093.x"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4725.2006.32335.x"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.136.4.487"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.134.3.301"},{"issue":"4","key":"e_1_2_6_18_1","first-page":"S75","article-title":"The treatment of focal hyperhidrosis with botulinum toxin","volume":"113","author":"Naver H","year":"1997","journal-title":"Eur J Neurol"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1524-4725.2002.01252.x"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2168.2001.01763.x"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.det.2014.06.013"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2003.12.029"},{"key":"e_1_2_6_23_1","first-page":"702","article-title":"Development, validity, and reliability of the Hyperhidrosis Impact Questionnaire? (HHIQ)","volume":"11","author":"Teale C","year":"2002","journal-title":"Qual Life Res"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1995.tb16953.x"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2007.01.009"}],"container-title":["Pediatric Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fpde.12620","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/pde.12620","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/pde.12620","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/pde.12620","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T11:13:18Z","timestamp":1696158798000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/pde.12620"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6,8]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["10.1111\/pde.12620"],"URL":"https:\/\/doi.org\/10.1111\/pde.12620","archive":["Portico"],"relation":{},"ISSN":["0736-8046","1525-1470"],"issn-type":[{"value":"0736-8046","type":"print"},{"value":"1525-1470","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6,8]]}}}